DOP2023000029A - Nueva composición de anticonceptivo oral de liberación modificada - Google Patents

Nueva composición de anticonceptivo oral de liberación modificada

Info

Publication number
DOP2023000029A
DOP2023000029A DO2023000029A DO2023000029A DOP2023000029A DO P2023000029 A DOP2023000029 A DO P2023000029A DO 2023000029 A DO2023000029 A DO 2023000029A DO 2023000029 A DO2023000029 A DO 2023000029A DO P2023000029 A DOP2023000029 A DO P2023000029A
Authority
DO
Dominican Republic
Prior art keywords
release oral
oral contraceptive
modified release
new composition
ethinylestradiol
Prior art date
Application number
DO2023000029A
Other languages
English (en)
Spanish (es)
Inventor
Colli Enrico
Original Assignee
Chemo Res S L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemo Res S L filed Critical Chemo Res S L
Publication of DOP2023000029A publication Critical patent/DOP2023000029A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
DO2023000029A 2020-08-14 2023-02-10 Nueva composición de anticonceptivo oral de liberación modificada DOP2023000029A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20382753.0A EP3954364A1 (en) 2020-08-14 2020-08-14 New modified release oral contraceptive composition
PCT/EP2021/072584 WO2022034209A1 (en) 2020-08-14 2021-08-13 New modified release oral contraceptive composition

Publications (1)

Publication Number Publication Date
DOP2023000029A true DOP2023000029A (es) 2023-07-09

Family

ID=72145348

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2023000029A DOP2023000029A (es) 2020-08-14 2023-02-10 Nueva composición de anticonceptivo oral de liberación modificada

Country Status (21)

Country Link
US (3) US12409141B2 (enExample)
EP (2) EP3954364A1 (enExample)
JP (1) JP2023538030A (enExample)
KR (1) KR20230067614A (enExample)
CN (1) CN116322701A (enExample)
AU (1) AU2021325372A1 (enExample)
BR (1) BR112023002654A2 (enExample)
CA (1) CA3191326A1 (enExample)
CL (1) CL2023000450A1 (enExample)
CO (1) CO2023002874A2 (enExample)
CR (1) CR20230127A (enExample)
DO (1) DOP2023000029A (enExample)
EC (1) ECSP23016038A (enExample)
IL (1) IL300578A (enExample)
JO (1) JOP20230032A1 (enExample)
MX (1) MX2023001868A (enExample)
PE (1) PE20231378A1 (enExample)
PY (1) PY2168235A (enExample)
UY (1) UY39379A (enExample)
WO (1) WO2022034209A1 (enExample)
ZA (1) ZA202303273B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20260021110A1 (en) * 2024-07-18 2026-01-22 Chemo Research, S.L. Methods of oral contraception by controlled release of dienogest and ethynyl estradiol
WO2026146125A1 (en) 2024-12-30 2026-07-09 Chemo Research, S.L. Treatment of hirsutism, polycystic ovarian syndrome and other associated conditions

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5340585A (en) 1991-04-12 1994-08-23 University Of Southern California Method and formulations for use in treating benign gynecological disorders
WO1997004752A1 (en) * 1995-07-26 1997-02-13 Duramed Pharmaceuticals, Inc. Pharmaceutical compositions of conjugated estrogens and methods for their use
US7589082B2 (en) 2003-06-13 2009-09-15 Skendi Finance Ltd Pharmaceutical formulation for contraception and hormone-replacement therapy
EP1690529A1 (de) 2005-02-15 2006-08-16 Schering AG Feste perorale Arzneiform zur Kontrazeption, die Dienogest und Ethinylestradiol enthält
DK1848406T3 (da) * 2005-02-15 2008-09-15 Jenapharm Gmbh Fast, penoral lægemiddelform til kontraception, der indeholder dienogest og ethynylestradiol
DE102005034498A1 (de) * 2005-07-20 2007-01-25 Grünenthal GmbH Orale Kontrazeption mit Trimegeston
TW201008569A (en) * 2008-08-08 2010-03-01 Bayer Schering Pharma Ag Progestin-containing drug delivery system

Also Published As

Publication number Publication date
UY39379A (es) 2022-01-31
CO2023002874A2 (es) 2023-04-05
CR20230127A (es) 2023-06-23
MX2023001868A (es) 2023-05-09
CN116322701A (zh) 2023-06-23
US12409141B2 (en) 2025-09-09
IL300578A (en) 2023-04-01
PE20231378A1 (es) 2023-09-07
US20260027058A1 (en) 2026-01-29
AU2021325372A1 (en) 2023-03-30
EP3954364A1 (en) 2022-02-16
US12409142B2 (en) 2025-09-09
CL2023000450A1 (es) 2023-10-20
WO2022034209A1 (en) 2022-02-17
JOP20230032A1 (ar) 2023-02-13
ECSP23016038A (es) 2023-04-28
EP4196098A1 (en) 2023-06-21
JP2023538030A (ja) 2023-09-06
US20240041775A1 (en) 2024-02-08
BR112023002654A2 (pt) 2023-04-04
ZA202303273B (en) 2026-02-25
PY2168235A (es) 2022-04-25
US20240350415A1 (en) 2024-10-24
CA3191326A1 (en) 2022-02-17
KR20230067614A (ko) 2023-05-16

Similar Documents

Publication Publication Date Title
CO2023002874A2 (es) Nueva composición de anticonceptivo oral de liberación modificada
AR059174A1 (es) Formas farmaceuticas en forma de pelicula para usar en la cavidad bucal (obleas)
PE20120860A1 (es) Combinacion farmaceutica que comprende levonorgestrel en combinacion con piroxicam, indometacina o diclofenaco
AR022008A1 (es) Una composicion de liberacion controlada de galantamina, un proceso para la preparacion de la misma, y el uso de dicha composicion para la preparacion de un medicamento
BR112022010899A2 (pt) Produto oral com componente dissolúvel
BRPI1007945C1 (pt) composição farmacêutica, comprimido, e, usos de nitazoxanida ou de um seu análogo
ECSP088390A (es) Método para la anticoncepción hormonal preventiva bajo demanda
BRPI0512991A (pt) uso de uma progestina, kit farmaceuticamente útil adaptado para a administração oral diária, e, método de contracepção em uma fêmea em idade de parto
BR0107972A (pt) Uso de uma proteìna ou polinucleotìdeo tat do hiv, nef do hiv, ou tat do hiv ligado(a) a uma proteìna ou polinucleotìdeo nef do hiv (nef-tat), e de uma proteìna ou polinucleotìdeo gp120 do hiv, método para imunizar um ser humano contra o hiv, e, composição de vacina para o uso humano
AR057060A1 (es) Composiciones de tanaproget que contienen etinil estradiol
DE502008002148D1 (de) Arzneimittel umfassend wenigstens ein gestagen
PE20040068A1 (es) Decanoato, undecanoato y dodecanoato de etonogestrel
MX2024009584A (es) Metodos anticonceptivos con efectos de sangrado programado.
PE20090805A1 (es) COMBINACION DE DROSPIRENONA Y 17ß-ESTRADIOL COMO CONTRACEPTIVO ORAL
AR120976A1 (es) Sistema para proporcionar un control de la natalidad
CY1111406T1 (el) Χρηση βαλερικης οιστραδιολης ή οιστραδιολης σε συνδυασμο με διενογεστη για την απο του στοματος θεραπεια της αιμορραγιας λογω δυσλειτουργιας της μητρας με τη μορφη απο του στοματος αντισυλληψης
PA8802001A1 (es) Combinación antiretroviral novedosa
BRPI0511864A (pt) uso de uma combinação de etinilestradiol e acetato de clormadinona para a preparação de um medicamento
BR112022011992A2 (pt) Composições para higiene bucal
CL2008003920A1 (es) Compuesto derivado de gama-lactona del esteroide del acido 15,16-metilen-17-hidroxi-19-nor-21-carboxilico, dispositivo intrauterino que lo contiene y su uso para la contracepcion oral y para trastornos pre, peri y postmenopausicos.
ECSP23031196A (es) Composición farmacéutica adecuada para administración vaginal en forma de óvulos y uso de la misma
CY1112775T1 (el) Χρηση βαλεριανικης οιστραδιολης σε συνδυασμο με dienogest για την απο του στοματος θεραπεια της δυσλειτουργικης αιμορραγιας της μητρας σε ενοτητα με αντισυλληψη απο του στοματος
CL2024003018A1 (es) Uso de prednisolona o sus sales farmacéuticas activas en una composición farmacéutica, proceso y uso
AR128632A1 (es) Anticonceptivo oral masticable de drospirenona
PE20070769A1 (es) Procedimiento para la produccion de una preparacion farmaceutica monofasica para la terapia oral de la hemorragia uterina disfuncional